• CASE STUDY: Deployment of Partek® Flow® on Amazon Web Services by Quadrant Biosciences

    February 12, 2018
    With the exponential growth of the amount of genomics data, analysis on the cloud has become an appealing alternative to deal with the data deluge. Quadrant Biosciences, a translational science company in New York state, recently launched Partek Flow on the Amazon Web Services (AWS) cloud. We caught up with them to discuss their work and their experience analyzing genomics data using Partek Flow on AWS.
  • Lexogen and Partek Deliver QuantSeq Analysis Solution

    November 28, 2017
    Partek and Lexogen scientists have joined forces to deliver an easy-to-use analysis pipeline in Partek Flow software for data generated by Lexogen’s QuantSeq 3’ Library Prep Kits. 
  • Partek Flow with New Genomic File System

    November 21, 2017
    Partek® Flow® software is now equipped with a new, proprietary Genomic File System. It intelligently reduces redundant data allowing you to reduce disk usage and process data faster, without the loss of information.
  • Would You Like Some Single Cells on Top, Perhaps?

    October 11, 2017
    By: Ivan Lukic, PhD - Field Application Scientist, Partek Incorporated

    If you are even marginally involved in molecular biology these days, wherever you go or whatever you do (attend a keynote lecture at a conference, follow a blog, grab a recent copy of a journal from the library shelf, or browse a Twitter feed) single cell-related technologies are everywhere. Everywhere! You cannot avoid it. It is no longer possible. For instance, the other day I called a local takeaway and the guy who was taking my order asked me if I wanted some single cells on top of my pizza.
  • How I Found Clinically Actionable Variants in cfDNA from Cancer Patients

    September 27, 2017
    By: Eric Sieser, PhD - Field Application Scientist, Partek Incorporated

    Precision medicine offers the promise of selecting treatments based on the genetic characteristics of an individual. Cancer, which is estimated to be responsible for over 600,000 deaths in 2017 within the US alone, is a disease where precision medicine could be instrumental in improving disease outcomes.  Genomic profiling has identified numerous somatic mutations with clinical relevance, such as EGFR mutations that guide gefitinib therapy in lung cancer, but only a small fraction of cancer drugs approved by the FDA have molecular predictors of efficacy. To realize the promise of precision medicine in cancer, continued research is critical. 
  • Introducing Partek Genomics Suite version 7.0

    September 27, 2017
    Partek Genomics Suite 7.0 is now released. It's modern, fast, and smarter than ever for quick and easy data analysis. Read all about the exciting updates.
  • Partek Celebrates Six Thousandth Citation

    August 8, 2017
    Genomics plays key role in metabolic disease study
    Partek genomic analysis software recently received its six thousandth citation in the June edition of Science Translational Medicine. To celebrate, Partek reached out to the authors of the paper that brought them to this milestone: Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β.
  • Researcher identified a novel cancer prognostic marker using 6,260 small non-coding RNA samples

    April 28, 2017
    Customer Interview by Cherry Ignacio - Field Application Scientist, Partek Incorporated
    Paraphrased for clarity

    We recently caught up with researcher Victor Martinez, Ph.D. of BC Cancer Agency to discuss his work with piRNAs using Partek Flow software, which allowed him to efficiently analyze one of the worlds biggest cohorts of sncRNAs.
  • X-Seq Story: On Failure of Molecular Biology and Being Fat

    February 2, 2017
    By: Ivan Lukic - Field Application Scientist, Partek Incorporated

    I recently had dinner with an old friend, a scientist and former faculty member at a top university and now at a biotechnology entrepreneurship. On our way there he challenged me by verbalizing his disappointment in modern biology. In his opinion, there has been no significant discovery in biology since the 60s and the deciphering of the genetic code. While that viewpoint could be considered extreme, it made me wonder what the next epic breakthrough might be.
  • Zika Research Advances Through Next Generation Sequencing

    December 7, 2016
    By: Ivan Lukic - Field Application Scientist, Partek Incorporated

    The Zika virus outbreak has been headline news throughout 2016 for good reason. According to the World Health Organization, 75 countries since 2007 have reported cases of Zika virus with 92% of those occurring between 2015 and 2016. Since no specific therapy is available, a number of research groups are focusing on the pathogenesis of Zika virus infection.